- In March 2024, CollPlant Biotechnologies, a regenerative medicine company, announced the successful preclinical results of its collagen-based synthetic bio-ink, designed for 3D bioprinting of tissues and organs. The bio-ink, made from recombinant human collagen, demonstrated excellent biocompatibility and structural support for tissue regeneration. This advancement reinforces CollPlant’s position as a pioneer in biofabrication and highlights the increasing convergence of synthetic biomaterials and 3D printing in tissue engineering applications
- In February 2024, BICO Group AB, a global leader in bio convergence technologies, introduced BIO X6, a six-printhead 3D bioprinter designed for multi-material tissue fabrication using synthetic hydrogels and polymers. The system allows for high-throughput printing of complex tissues and supports pharmaceutical research and regenerative medicine development. This innovation showcases the growing role of customizable, synthetic scaffold solutions in next-generation medical applications
- In January 2024, RevBio, Inc. received FDA Breakthrough Device Designation for its TETRANITE synthetic bone adhesive, intended for cranial and orthopedic applications. This synthetic biomaterial enables rapid bone regeneration and stable fixation, significantly improving outcomes over traditional grafting methods. The recognition marks a major milestone in accelerating regulatory pathways for synthetic tissue engineering products
- In December 2023, researchers at University of Cambridge partnered with a biotech startup to develop electrospun nanofiber scaffolds made from synthetic biodegradable polymers for nerve regeneration. The project received funding from the U.K. Research and Innovation (UKRI) and targets clinical trials in 2025. The innovation underscores the potential of synthetic nanomaterials in addressing complex neurological injuries
- In October 2023, DSM Biomedical, a leading biomaterials company, launched a new line of customizable synthetic polymers specifically engineered for use in cardiovascular and dental tissue engineering. These materials feature tunable degradation rates and improved cell-adhesion properties, catering to device manufacturers seeking scalable synthetic solutions. This development reflects the expanding demand for specialized, application-specific synthetic biomaterials in the medical field
